September 29, 2019
3 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Sustained-release dexamethasone implant puts compliance in surgeon’s hands
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARIS — At the European Society of Cataract and Refractive Surgeons meeting, John A. Hovanesian, MD, speaks about the advantages of using sustained-release Dextenza (Ocular Therapeutix) to treat pain and inflammation after cataract surgery. Dextenza is designed to go in the lower lid punctum and slowly release dexamethasone in the tear film over 1 month, thus eliminating compliance issues for patients who would otherwise use steroid eye drops postoperatively. Data from three FDA clinical trials are now available.